NeutroGen Therapeutics

NeutroGen Therapeutics (NTX) is developing a novel allogeneic neutrophil cell therapy for neutropenia—a condition prevalent in leukemia patients and individuals undergoing chemotherapy, associated with high infection risk and mortality. NTX’s patent-pending therapy uses a stem cell-based protocol that enables the production of storable, genetically modifiable neutrophils, providing a faster, more reliable treatment. The platform also holds promise for expansion into cancer, autoimmunity, and multi-drug resistance indications.